ADCT ADC Therapeutics SA

NYSE
$1.01

ADC Therapeutics SA (ADCT) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.6% since its last earnings release on August 13, 2026.

ADC Therapeutics SA Beat Consensus Estimates
Thursday, August 13, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 7:30 AM ET
Earnings Whisper
-
vs ($0.21)
Rev est $20.55M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.03

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ADC Therapeutics SA

ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow